Australia’s TGA Approves Psychedelics To Treat Mental Health Conditions

Global News

Australia’s TGA approves psychedelics to treat mental health conditions

Australia’s Therapeutic Goods Administration (TGA) has announced its approval of the use of psychedelics to treat certain mental health conditions. From 1 July 2023, medicines containing the psychedelic substances psilocybin (found in hallucinogenic fungi, also known as magic mushrooms) and MDMA can be prescribed by authorised psychiatrists to treat selected mental health conditions.

There is currently evidence that psychedelics have benefits for treating patients with post-traumatic stress disorder (PTSD) and depression, so it is only these two conditions for which the drugs can be prescribed. MDMA will be approved for PTSD while psilocybin will be approved for treatment-resistant depression.

This approval marks the TGA’s acknowledgement of the lack of treatments for some treatment-resistant mental health conditions, meaning the drugs will be able to be used therapeutically in a controlled medical setting.

Only psychiatrists approved under the TGA’s Authorised Prescriber Scheme will be able to prescribe these drugs, however there are currently no approved products containing the substances that have been assessed for safety, efficacy and quality, so psychiatrists will have access to ‘unapproved’ medicines to prescribe to their patients. For medical purposes the substances will be listed as Schedule 8 (controlled drugs) medicines in Australia’s Poisons Standard, but for all other uses they remain classified as Schedule 9(prohibitedsubstances).

Sarah-Catherine Rodan, PhD student at the University of Sydney, commented: “Safety and efficacy have been demonstrated in other indications such as nicotine/alcohol dependence, obsessive compulsive disorder and end-of-life distress. Further, depression is often co-occurring with these psychiatric disorders. The TGA clearly acknowledges that it does have therapeutic value and states that these substances are relatively safe when administered in a medically controlled environment.”

Professor Peter Duggan, senior principal research scientist at CSIRO believes this news is “really promising” for patients with these difficult-to-treat conditions, adding that it will “also be great encouragement for a number of local Australian companies whose goal is to commercialise psychedelic therapies based on psilocybin or MDMA.”

First Indian Intranasal COVID-19 Vaccine Recently Launched

Bharat Biotech has recently launched its new intranasal COVID-19 vaccine iNCOVACC

Drug-resistant Bacterium Found In Eye Drops Has Infected 55 People In 12 States

A strongly drug-resistant bacterium has been found in various brands of artificial tears eye drops, infecting 55 people throughout 12 states

Johnson & Johnson Subsidiary Loses US Bankruptcy Bid

A subsidiary of J&J has lost a bankruptcy petition aiming to transfer thousands of legal claims against the subsidiary related to the claim that its talcum powder causes cancer

WHO Issues A ‘Call To Action’ After Cough Syrup Deaths

WHO has issued a 'call to action' to all member states in order to try to prevent, detect and respond to incidences of illegitimate medical products

Stand Up To Cancer Announces Four Teams Dedicated To Increasing Diversity In Clinical Trials

SU2C has announced four teams focusing on increasing diversity in early phase cancer clinical trials

First Indian Intranasal COVID-19 Vaccine Recently Launched

Drug-resistant Bacterium Found In Eye Drops Has Infected 55 People In 12 States

Johnson & Johnson Subsidiary Loses US Bankruptcy Bid

WHO Issues A ‘Call To Action’ After Cough Syrup Deaths

Stand Up To Cancer Announces Four Teams Dedicated To Increasing Diversity In Clinical Trials

Pharmafocus

Categories

Social Footprints